Moreover, the 36-month beta value for BBIO is 1.07. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BBIO is 146.91M and currently, short sellers hold a 12.68% of that float. On October 16, 2024, BBIO’s average trading volume was 1.92M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BBIO) stock’s latest price update
The stock price of BridgeBio Pharma Inc (NASDAQ: BBIO) has plunged by -1.55 when compared to previous closing price of 25.78, but the company has seen a 2.63% gain in its stock price over the last five trading sessions. fool.com reported 2024-10-04 that Upcoming Food and Drug Administration decisions could push these stocks through the roof.
BBIO’s Market Performance
BridgeBio Pharma Inc (BBIO) has experienced a 2.63% rise in stock performance for the past week, with a -3.09% drop in the past month, and a -9.32% drop in the past quarter. The volatility ratio for the week is 5.87%, and the volatility levels for the past 30 days are at 4.82% for BBIO. The simple moving average for the past 20 days is 0.54% for BBIO’s stock, with a -12.38% simple moving average for the past 200 days.
Analysts’ Opinion of BBIO
Piper Sandler, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $46. The rating they have provided for BBIO stocks is “Overweight” according to the report published on September 04th, 2024.
Raymond James gave a rating of “Outperform” to BBIO, setting the target price at $45 in the report published on March 21st of the current year.
BBIO Trading at -2.02% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.73% of loss for the given period.
Volatility was left at 4.82%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares sank -5.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.47% lower at present.
During the last 5 trading sessions, BBIO rose by +2.63%, which changed the moving average for the period of 200-days by -39.30% in comparison to the 20-day moving average, which settled at $25.24. In addition, BridgeBio Pharma Inc saw -37.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from KKR Genetic Disorder L.P., who sale 5,800,000 shares at the price of $25.75 back on Sep 13 ’24. After this action, KKR Genetic Disorder L.P. now owns 25,260,971 shares of BridgeBio Pharma Inc, valued at $149,350,000 using the latest closing price.
KKR Genetic Disorder L.P., the Affiliate of BridgeBio Pharma Inc, proposed sale 5,800,000 shares at $26.95 during a trade that took place back on Sep 13 ’24, which means that KKR Genetic Disorder L.P. is holding shares at $156,310,000 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -2.3 for the present operating margin
- 0.98 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -2.07. The total capital return value is set at -0.76.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated 2.74 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at -1.58. The interest coverage ratio of the stock is -10.87.
Currently, EBITDA for the company is -574.64 million with net debt to EBITDA at -2.4. When we switch over and look at the enterprise to sales, we see a ratio of 27.17. The receivables turnover for the company is 332.01for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.
Conclusion
To wrap up, the performance of BridgeBio Pharma Inc (BBIO) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
